ArticleJournal of health economics and outcomes researchPublished
Estimated Cost of Adverse Event Management in Treatment Naïve Non-small Cell Lung Cancer Patients with Common EGFR Mutations Treated with Amivantamab Plus Lazertinib and Osimertinib Plus Chemotherapy
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Article
- Venue
- Journal of health economics and outcomes research
- Published
- Topic
- Public health
- Subject terms
- Non-small cell lung cancer; Cost Analysis; Egfr Mutations; Adverse Event Management; Amivantamab Plus Lazertinib; Proactive Therapy Management
- PubMed ID
- 42170243
- PubMed Central ID
- PMC13189261
- Open access
- Yes, open
- Added to directory
- Source checked